ROS1
Showing 1 - 25 of 991
Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- +4 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)
Recruiting
- Protein Kinase Inhibitors
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Nov 9, 2023
NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)
Not yet recruiting
- Non-Small Cell Lung Cancer(NSCLC)
- WX-0593 Tablets
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Mar 1, 2023
NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaDepartment of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)
Not yet recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Providence, Rhode IslandRhode Island Hospital, Brown University
Mar 2, 2023
Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)
Recruiting
- Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's hospital
May 31, 2022
Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)
Recruiting
- Nonsmall Cell Lung Cancer
-
Goyang-Si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory
Withdrawn
- Advanced Malignant Neoplasm
- +10 more
- Brigatinib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged
Withdrawn
- Non-Small Cell Lung Cancer
- InVisionFirst-Lung ctDNA assay
-
Los Angeles, California
- +2 more
Sep 16, 2022
Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1
Completed
- Lung Cancer ROS Translocated
-
Créteil, FranceCHI Créteil
Nov 19, 2021
First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 1, 2022
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- XZP-5955 tablets
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
May 17, 2022
Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,
Recruiting
- Invasive Lobular Breast Carcinoma
- +2 more
- Entrectinib
- +2 more
-
Brussels, Belgium
- +9 more
May 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)
Recruiting
- ROS1 Rearrangement Non-small Cell Lung Cancer
- ALK Rearrangement Non-small Cell Lung Cancer
-
ShangHai, Shanghai, ChinaShanghai Chest hospital affiliated to Shanghai jiao tong univers
Sep 14, 2021
Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)
Recruiting
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
-
Orange, California
- +18 more
Oct 6, 2022
Safety and Efficacy of Xalkori ROS1
Recruiting
- Non-small Cell Lung Cancer
-
Tokyo, JapanPfizer local country office
Aug 26, 2021
Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))
Not yet recruiting
- Lung Cancer
- Non Small Cell Lung Cancer
- Amivantamab 1050mg
- +2 more
-
Aurora, Colorado
- +2 more
Apr 25, 2023
PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene
Recruiting
- Non Small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Mar 9, 2022
Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)
Recruiting
- Nsclc
- +5 more
- Pembrolizumab
- +3 more
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 25, 2021
Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (TPX-0005, Metformin Hydrochloride, Digoxin)
Recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- TPX-0005
- +3 more
-
Canton, OhioGabrail Cancer Research Center
Apr 25, 2023
Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)
Active, not recruiting
- Hematologic Cancers
- +2 more
-
Villejuif, Ile De France, FranceGustave Roussy
Sep 5, 2022
Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Tumor-infiltrating Lymphocytes (TIL)
- +5 more
-
Tampa, FloridaMoffitt Cancer Center
Dec 28, 2022
Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI
Recruiting
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- +5 more
-
Aurora, ColoradoUniversity of Colorado, Cancer Center
Nov 3, 2021
NSCLC Trial in Guangzhou (TGRX-326)
Recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 29, 2022